@article{39cefc64ed654ede89a26f296d0ca47a,
title = "Emerging roles of innate and adaptive immunity in Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most common neurodegenerative disease, with characteristic extracellular amyloid-β (Aβ) deposition and intracellular accumulation of hyperphosphorylated, aggregated tau. Several key regulators of innate immune pathways are genetic risk factors for AD. While these genetic risk factors as well as in vivo data point to key roles for microglia, emerging evidence also points to a role of the adaptive immune response in disease pathogenesis. We review the roles of innate and adaptive immunity, their niches, their communication, and their contributions to AD development and progression. We also summarize the cellular compositions and physiological functions of immune cells in the parenchyma, together with those in the brain border structures that form a dynamic disease-related immune niche. We propose that both innate and adaptive immune responses in brain parenchyma and border structures could serve as important therapeutic targets for treating both the pre-symptomatic and the symptomatic stages of AD.",
keywords = "Alzheimer's disease, adaptive immunity, immune niche, innate immunity",
author = "Xiaoying Chen and Holtzman, {David M.}",
note = "Funding Information: This work was supported by a Carol and Gene Ludwig Award for Neurodegeneration Research (D.M.H.), National Institute of Health grants RF1NS090934 and RF1AG047644 (D.M.H.), the JPB Foundation (D.M.H.), and Cure Alzheimer{\textquoteright}s Fund (D.M.H.). Figures were created by BioRender. Funding Information: This work was supported by a Carol and Gene Ludwig Award for Neurodegeneration Research (D.M.H.), National Institute of Health grants RF1NS090934 and RF1AG047644 (D.M.H.), the JPB Foundation (D.M.H.), and Cure Alzheimer's Fund (D.M.H.). Figures were created by BioRender. X.C. wrote the draft of the manuscript. D.M.H. reviewed and edited the manuscript. D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies and on a patent licensed to NextCure on anti-ApoE antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory boards of Denali, Genentech, and Cajal Neuroscience and consults for Alector. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = dec,
day = "13",
doi = "10.1016/j.immuni.2022.10.016",
language = "English",
volume = "55",
pages = "2236--2254",
journal = "Immunity",
issn = "1074-7613",
number = "12",
}